Document:

Exhibit 10.2

 

 

 

	employment
    AGREEMENT PURSUANT TO
	SECTION
    7:610 (et seq.) of the Dutch Civil
	Code
    (DCC)

 

August 20, 2019

 

Employment agreement between

 

		(1)	uniQure
                                         biopharma B.V., a company with limited liability (besloten vennootschap met beperkte
                                         aansprakelijkheid), with registered office at Amsterdam and principal place of business
                                         at Paasheuvelweg 25a, (1105 BP) Amsterdam (the Employer); and

 

		(2)	Sander
                                         van Deventer born on November 1, 1954 (the Employee);

 

	 	 	each “a Party”, collectively, “the Parties”.

 

The Parties agree as follows:

 

		1	Commencement
                                         date Agreement and position

 

		1.1	On
                                         August 20, 2019 (the “Effective Date”), this employment agreement (the “Agreement”)
                                         will become effective and Employee shall continue his employment with Employer in a new
                                         role, assuming a part-time (80%), 0.8 FTE, position with the Employer in the position
                                         of Executive Vice President, Research and Product Development. Employee undertakes to
                                         perform all the activities as set out in Exhibit A (Job Description) and that can reasonably
                                         be assigned to him by or on behalf of the Employer and which are related to the Employer's
                                         business. To the best of his ability in doing so, the Employee will comply with the instructions
                                         given to him by or on behalf of the Employer.

 

		1.2	This
                                         Agreement replaces and supersedes the prior Employment Agreement dated August 4, 2017,
                                         which is contemporaneously terminated as of the Effective Date of this Agreement.

 

		1.3	The
                                         Employer shall be entitled to assign other duties than the usual activities of the Employee,
                                         or to alter the position of the Employee if in the reasonable opinion of the Employer
                                         the business circumstances so require.

 

		1.4	The
                                         Employee shall not be engaged in any business activity which, in the judgment of the
                                         Employer, conflicts with Employee’s ability to carry out his duties for the Employer,
                                         whether or not such activity is pursued for pecuniary advantage, without the approval
                                         of the Board of Directors of uniQure N.V (the “Board”), other than business
                                         activities undertaken in his capacity as a general partner or venture partner of Forbion
                                         Capital Partners or its affiliated funds for up to 20% of his time. It is the mutual
                                         understanding that the Employee has resigned as Managing Partner of Forbion Capital Partners,
                                         it being understood that the Employee will thereafter continue as a venture partner or
                                         similar function with Forbion Capital Partners or its affiliated funds for up to 20%
                                         of his time.

 

		1.5	The
                                         work will be performed at the office of the Employer at Paasheuvelweg 25a (1105 BP) in
                                         Amsterdam provided, however, that the Employee shall be required to travel from time
                                         to time for business purposes. The Employer reserves the right to change the location
                                         where the work is performed after consultation with the Employee.

 

		1.6	The
                                         normal working hours for a full-time, 1.0 FTE position are 40 hours per week. The working
                                         hours are normally 8.5 hours a day with a thirty (30) minute lunch break.

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 1
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

		2	Term
                                         and termination Agreement

 

		2.1	The
                                         Agreement has been entered into for an indefinite period of time.

 

		2.2	The
                                         Agreement will in any event, without notice being required, terminate as of the first
                                         day of the month following the date the Employee reaches the State pension age (AOW-gerechtigde
                                         leeftijd).

 

		2.3	The
                                         Agreement can be terminated by each of the Parties with due observance of the statutory
                                         notice period of 4 months for the Employer and 2 months for the Employee.

 

		2.4	Severance
                                         Payments.

 

		2.4.1	lf
                                         the Agreement is terminated on the initiative of Employer, other than in the case of
                                         summary dismissal as referred to in article 7:677 of the Dutch Civil Code, long-term
                                         illness (article 7:669 section 3 under b Dutch Civil Code) or severely culpable acts
                                         or omissions by Employee as referred to in article 7:669 section 3 under the Dutch Civil
                                         Code, Employer shall grant the Employee severance pay equal to 100% of (i) the annual
                                         prorated base salary excluding 8% holiday allowance, plus (ii) the amount of the Target
                                         Bonus (i.e., 40% of the annual Pro-rata Base Salary (as defined in Clause 3)),
                                         excluding holiday allowance, (hereinafter: 'Severance Pay') subject to deductions that
                                         are authorized by Employee and/or required by applicable laws and regulations.

 

		2.4.2	lf
                                         the Agreement is terminated on the initiative of Employer within twelve (12) months of
                                         a Change of Control (as defined below), other than in the case of summary dismissal as
                                         referred to in article 7:677 of the Dutch Civil Code, long-term illness (article 7:669
                                         section 3 under b Dutch Civil Code) or severely culpable acts or omissions by Employee
                                         as referred to in article 7:669 section 3 under the Dutch Civil Code, claus 2.4.1 shall
                                         not apply and, instead, Employer shall grant the Employee severance pay equal to 150%
                                         of (i) the annual prorated base salary excluding 8% holiday allowance, plus (ii) the
                                         amount of the Target Bonus (i.e., 40% of the annual Pro-rata Base Salary), excluding
                                         holiday allowance, (hereinafter: 'Severance Pay on a Change of Control') subject to deductions
                                         that are authorized by Employee and/or required by applicable laws and regulations. Employer
                                         shall not owe any payments or partial payments of any kind under both clauses 2.4.1 and
                                         2.4.2, which are mutually exclusive.

 

		2.4.3	If
                                         Severance Pay under clause 2.4.1 or Severance Pay on a Change of Control under clause
                                         2.4.2 is owed to the Employee, then the Employer shal grant the Employee additional severance
                                         pay equal to a prorated Target Bonus amount for the year of termination as provided in
                                         this clause (the “Pro-rata Bonus”). The Pro-rata Bonus shall be the product
                                         of the formula B x D/365 where B represents the Target Bonus (i.e., 40% of the
                                         annual Pro-rata Base Salary)), and D represents the number of days elapsed in the calendar
                                         year through the date of the separation of Executive’s employment from the Employer.

 

		2.4.4	lf
                                         and insofar as Employee is entitled to the transition payment as referred to in article
                                         7:673 of the Dutch Civil Code, this transition payment shall be deemed to be factored
                                         into the Severance pay, the Severand pay on a Change of Control, and the Pro-Rata Bonus.

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 2
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

		2.4.5	In
                                         the event of a termination under this clause 2.4, the Employer shall provide 4 months'
                                         notice to the Employee. The Employer, in its sole discretion subject to applicable law,
                                         may choose to put the Employee on garden leave at any time during the notice period.
                                         Garden leave will be consldered equal to continuation of full time employment, but the
                                         Employee will be released trom his working duties. In the event that the Employee is
                                         placed on garden leave, the amount of the severance pay under this clause 2.4 will be
                                         reduced by an amount equivalent to the salary during the Employee's garden leave, and
                                         the effective date of the garden leave shall be the the date of the separation of Executive’s
                                         employment from the Employer for purposes of calculating the Pro-rata Bonus of clause
                                         2.4.3.

 

		2.4.6	In
                                         the event of a Change of Control as defined below, the vesting conditions that may apply
                                         to any stock options, restricted shares, restricted stock units, performance stock units
                                         or other grants of equity held by Executive pursuant to this Agreement and the Company’s
                                         Amended and Restated 2014 Share Incentive Plan will be automatically waived and shall
                                         be deemed fully vested immediately prior to the Change of Control event. All Stock Options
                                         will be deeed to be fully exercisable commencing on the date of and immediately prior
                                         to the Change of Control and ending on the eighteen (18) month anniversary of the Change
                                         of Control or, if earlier, the expiration of the term of such Stock Options.

 

		2.4.7	For
                                         purposes of this Agreement, “Change of Control” shall mean the date on which
                                         any of the following events occurs:

 

		2.4.7.1	any
                                         “person,” as such term is used in Sections 13(d) and 14(d) of the United
                                         States Securities Exchange Act of 1934, as amended (the “Act”) (other than
                                         uniQure N.V. (the “Company”), any of its subsidiaries, or any trustee, fiduciary
                                         or other person or entity holding securities under any employee benefit plan or trust
                                         of the Company or any of its subsidiaries), together with all “affiliates”
                                         and “associates” (as such terms are defined in Rule 12b-2 under the Act)
                                         of such person, shall become the “beneficial owner” (as such term is defined
                                         in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing
                                         forty (40) percent or more of the combined voting power of the Company’s then outstanding
                                         securities having the right to vote in an election of the Board (“Voting Securities”)
                                         (in such case other than as a result of an acquisition of securities directly from the
                                         Company); or

 

		2.4.7.2	a
                                         majority of the members of the Board is replaced during any 12-month period by directors
                                         whose appointment or election is not endorsed by a majority of the members of the Board
                                         before the date of the appointment or election; or

 

		2.4.7.3	the
                                         consummation of (i) any consolidation or merger of the Company where the stockholders
                                         of the Company, immediately prior to the consolidation or merger, would not, immediately
                                         after the consolidation or merger, beneficially own (as such term is defined in Rule
                                         13d-3 under the Act), directly or indirectly, shares representing in the aggregate more
                                         than fifty (50) percent of the voting shares of the Company issuing cash or securities
                                         in the consolidation or merger (or of its ultimate parent corporation, if any), or (ii)
                                         any sale or other transfer (in one transaction or a series of transactions contemplated
                                         or arranged by any party as a single plan) of all or substantially all of the assets
                                         of the Company.

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 3
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

		3	Salary,
                                         bonus, equity and holiday allowance

 

		3.1	The                                          Employee’s annual salary will be EUR
                                                                                                       348.000,00 gross (the “Pro-rata Base Salary”) based on 0.8 FTE (i.e., 80% of EUR 435,000), including
                                                                                                       an 8% holiday allowance. The salary, including the holiday allowance, shall be paid in
                                                                                                       12 equal, monthly instalments of EUR 29.000,00.

 

		3.2	The
                                         Employee shall be eligible for a bonus payment amounting to a target amount of 40% of
                                         his Pro-rata Base Salary (the “Target Bonus”). The Employee’s eligibility
                                         for a Target Bonus or any other bonus payment shall be dependent on the Employer guidelines
                                         and is at the full discretion of the Board. 

 

		3.3	Except
                                         as provided in clause 2.4, bonus payments, if any, will not be taken into account for
                                         the calculation of any possible severance payment upon termination of the Agreement.
                                         To be eligible for any bonus pursuant to this Agreement or otherwise pursuant to Employee’s
                                         employment with Employer, Employee must be in service of Employer on the date any bonus
                                         is paid.

 

		3.4	Subject
                                         to Board of Directors’ approval at the next regularly scheduled uniQure N.V. Board
                                         meeting after execution of this Agreement, the Employee shall be granted Restricted Stock
                                         Units totaling 15,000 (fifteen thousand) ordinary shares of uniQure N.V., the terms of
                                         which shall reflect the standard three-year vesting and other terms and conditions contained
                                         in the uniQure N.V.’s Amended and Restated 2014 Share Incentive Plan. Such options
                                         will be approved by the Board of Directors of uniQure N.V. not later than at its next
                                         regularly scheduled meeting. The Executive will be eligible for future equity grants
                                         pursuant to the Company’s policies and procedures, which shall also be subject
                                         to pro-ration related to the Employee’s part-time status.

 

		4	Overtime

 

	 	 	The Employee undertakes to work overtime at the
    request of the Employer. The Employer does not pay any compensation for overtime.

 

		5	Expenses

 

		5.1	The
                                         costs for travelling from home to office shall be compensated in accordance with the
                                         Employer policy.

 

		5.2	To
                                         the extent that the Employer has given prior approval for business travels, the Employer
                                         shall reimburse reasonable travel and accommodation expenses relating to such business
                                         travel incurred by the Employee in the performance of his duties upon submission of all
                                         the relevant invoices and vouchers within 30 days following completion of the business
                                         travel.

 

		6	Holidays

 

		6.1	The
                                         Employee is entitled to 30 business days holiday per year or a pro rata portion thereof
                                         if the Agreement commences and/or terminates during the calendar year and/or the Employee
                                         works part-time.

 

		6.2	The
                                         statutory holiday days (20 days of the 30 per year on full time employment) shall be
                                         forfeited after 6 months after the end of the year in which the holiday days were accrued.

 

		6.3	The
                                         Employer shall determine the commencement and the end of the holiday in consultation
                                         with the Employee. The Employee shall take his holidays in the period that the activities
                                         best allow this.

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 4
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

		7	Illness

 

	 	 	In the event of illness in the sense of section
    7:629 Dutch Civil Code, the Employee must report sick to the Employer as soon as possible, but no later than 9 a.m. on the
    first day of illness. The Employee undertakes to comply with the rules related to reporting and inspection in the case of
    illness, as adopted from time to time by the Employer.
	 

		8	Insurance

 

	 	 	The Employer will comply with the obligations under
    the Dutch Health Care Insurance Act.

 

		9	Pension

 

	 	 	The Employee shall be entitled to participate
    in the pension scheme of the Employer following Employer guidelines.

 

		10	Confidentiality
                                         obligation

 

		10.1	Both
                                         during the term of the Agreement and after the Agreement has been terminated for any
                                         reason whatsoever, the Employee shall not make any statements in any way whatsoever to
                                         anyone whomsoever (including other personnel of the Employer, unless these should be
                                         informed of anything in connection with the work they perform for the Employer), regarding
                                         matters, activities and interests of a confidential nature related to the business of
                                         the Employer and/or the Employer’s affiliates, of which the Employee became aware
                                         within the scope of his work for the Employer and the confidential nature of which he
                                         is or should be aware (“Confidential Information”). The Confidential Information
                                         includes, inter alia, information about the Employer’s products, processes
                                         and services, including but not limited to, information relating to research, development,
                                         inventions, manufacture, purchasing, engineering, marketing, merchandising and selling.

 

		10.2	For
                                         all oral and written publications by the Employee, which can or could harm the interests
                                         of the Employer, prior approval from the Employer has to be obtained. This approval shall
                                         only be refused on sincere grounds based on those interests.

 

		10.3	All
                                         information exchanged via the Employer’s email system is considered to be Employer’s
                                         proprietary information and should be taken care of accordingly.

 

		10.4	The
                                         Employee agrees that the confidentiality obligations set forth in this clause 10 supersede
                                         the Employee’s obligations to any other company, fund or other organization with
                                         which the Employee may have a relationship (“Affiliated Entities”) and that
                                         any Confidential Information that Employee receives will only be used within the scope
                                         of his employment under this Agreement or any successor agreement with Employer and will
                                         not be used during the course of his relationship, or communicated through by any means
                                         to, any Affiliated Entity.

 

		11	Documents

 

	 	 	The Employee is prohibited from in any way having
    documents and/or correspondence and/or other information carriers and/or copies thereof in his possession that belong to the
    Employer and/or to the Employer’s affiliates, with the exception of the extent to which and as long as required for
    the performance of his activities for the Employer. In any event, the Employee is required, even without any request being
    made to that end, to return such documents and/or correspondence and/or other information carriers and/or copies thereof to
    the Employer immediately upon the end of the Agreement, or in the event the Employee is on non-active duty for any reason
    whatsoever.

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 5
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

		12	Ban
                                         on ancillary jobs

 

	 	 	During the term of the Agreement, without the prior
    written consent of the Employer, the Employee shall not accept any paid work or time-consuming unpaid work at or for third
    parties and will refrain from doing business for his own account, other than as provided in clause 1.4 above. For the avoidance
    of doubt the Employer shall not unreasonably withhold its consent for the Employee to take on any positions at third parties
    should the Employee fulfill such position as a Venture Partner of Forbion Capital Partners.

 

		13	Non-competition
                                         and business relationship clause

 

		13.1	Both
                                         during the term of the Agreement and for a period of one year after the Agreement has
                                         been terminated for any reason whatsoever, without the prior written consent of the Employer,
                                         the Employee shall not be engaged or involved or have any share in any manner whatsoever,
                                         directly or indirectly, whether on his own behalf or for third parties, in any enterprise
                                         which conducts activities in a field similar to or otherwise competing with that of the
                                         Employer and/or the Employer’s affiliates, nor act, in any manner whatsoever, directly
                                         or indirectly, whether on his own behalf or for third parties, as an intermediary in
                                         relation to such activities. The activities contemplated by clause 1.4 shall not be deemed
                                         to be in breach of this clause 13.1.

 

		13.2	Both
                                         during the term of the Agreement and for a period of one year after the Agreement has
                                         been terminated for any reason whatsoever, without the prior written consent of the Employer,
                                         the Employee shall not perform or have performed professional services in connection
                                         with any product or research or development or commercialization that competes with products,
                                         or research or development or commercialization of Employer, directly or indirectly,
                                         whether on his own behalf or for third parties, nor enter into contacts, in that respect,
                                         directly or indirectly, whether on his own behalf or for third parties, with clients
                                         and/or relations of the Employer and/or the Employer’s affiliates and/or purchasers
                                         of products and/or services of the Employer and/or the Employer's affiliates. The activities
                                         contemplated by clause 1.4 shall not be deemed to be in breach of this clause 13.2

 

		13.3	Clients
                                         and/or relations of the Employer and/or the Employer’s affiliates such as set out
                                         in article 13.2 of this Agreement shall in all events mean relations of the Employer
                                         and/or the Employer’s affiliates with which the Employer has or has had (business)
                                         contact in any manner whatsoever throughout the course of, or otherwise prior to the
                                         termination of, the Agreement.

 

		13.4	Both
                                         during the term of the Agreement and for a period of one year after the Agreement has
                                         been terminated for any reason whatsoever, without the prior written consent of the Employer,
                                         the Employee shall refrain from becoming engaged or involved in any manner whatsoever,
                                         directly or indirectly, whether on his own behalf or for third parties, in actively enticing
                                         away, taking (or causing to have taken) into employment, nor make use of, in any manner
                                         whatsoever, directly or indirectly, whether on his own behalf or for third parties, the
                                         type of work of employees or persons who in a period of one year prior to the termination
                                         of the Agreement of the Employee are or have been in the employment of the Employer and/or
                                         the Employer’s affiliates.

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 6
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

		13.5	Employee
                                         acknowledges and agrees to adhere to this clause as the Employer has a serious business
                                         interest in binding the Employee to the non-competition and business relationship clause,
                                         due to the fact that (i) within the organization of the Employer competition-sensitive
                                         information as well as confidential information related to the Employer and its clients
                                         and relations, such as but not limited to products, or research or development or commercialization
                                         of Employer (“Sensitive Business Information”) are available and (ii) in
                                         the position of Executive Vice President, Research
                                         and Product Development the Employee has access to this Sensitive Business
                                         Information and/or will become aware of this Sensitive Business Information and/or will
                                         maintain (commercial) contacts with clients, suppliers, competitors etc. Given the aforesaid
                                         considerations (i) and (ii) in this clause, combined with the education and capacities
                                         of the Employee, the Employer has a well-founded fear that its business interest will
                                         be harmed substantially if the Employee performs competing activities as set forth in
                                         clauses 13.1 up to and including 13.5 of the Agreement within a period of 12 months after
                                         termination of the Agreement.

 

		14	Intellectual
                                         and industrial property

 

		14.1	The
                                         Employer is or will be considered to be, to the fullest extent allowed by law, the maker/producer/designer/breeder
                                         of all that which is made, created, improved, produced, designed, invented or discovered
                                         by the Employee during his activities performed for the Employer (the Works).

 

		14.2	The
                                         Employee is obliged to fully and comprehensibly disclose all Works to the Employer in
                                         writing immediately after they are created or after the creation becomes known to the
                                         Employee, and in any case at the request of the Employer.

 

		14.3	The
                                         Employee hereby transfers and assigns all his rights to and in connection with the Works
                                         to the Employer in advance.

 

		14.4	The
                                         Employee is obliged, at first request of the Employer, to transfer and assign to the
                                         Employer all rights to and in connection with the Works that do not belong to the Employer
                                         by operation of law (van rechtswege), and that are not transferred to the Employer
                                         pursuant to article 14.3 of this Agreement. This concerns all rights, anywhere in the
                                         world, to and arising from or in connection with the Works. This obligation of the Employee
                                         remains in force even after the end of this Agreement.

 

		14.5	The
                                         Employee agrees to perform, to the extent necessary and/or at the request of the Employer,
                                         such further acts as may be necessary or desirable to apply for, obtain and/or maintain
                                         protection for the Works, inter alia by means of the establishment of intellectual
                                         and industrial property rights. The Employee hereby grants permission and power of attorney
                                         to the Employer to the extent necessary to carry out every required act on behalf of
                                         the Employee to obtain protection for the Works, or to transfer the Works and any rights
                                         relating thereto, to the Employer. The Employer will compensate the reasonable costs
                                         made in respect hereof, in so far as the payment that the Employee receives pursuant
                                         to article 3.1 of this Agreement cannot be considered as compensation for such costs.
                                         This obligation of the Employee remains in force even after the end of the Agreement.

 

		14.6	The
                                         Employee acknowledges that the payment ex article 3.1 of this Agreement includes a reasonable
                                         compensation for any possible deprivation of any intellectual and industrial property
                                         rights. To the extent legally possible, the Employee hereby waives his right to any additional
                                         compensation with respect to the Works.

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 7
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

		15	Gifts

 

	 	 	In connection with the performance of his duties,
    the Employee is prohibited from accepting or stipulating, either directly or indirectly, any commission, reimbursement or
    payment, in whatever form, or gifts from third parties other than those covered under article 1.4. The foregoing does not
    apply to standard promotional gifts having little monetary value.

 

		16	Penalty
                                         clause

 

	 	 	In the event the Employee acts in violation
    of any of the obligations under the articles 10 through 15 of this Agreement, the Employee shall, contrary to section 7:650
    paragraphs 3, 4 and 5 Dutch Civil Code, without notice of default being required, forfeit to the Employer for each such violation,
    a penalty in the amount of EUR 10.000,00 as well as a penalty of EUR 1.000,00 for each day such violation has taken place
    and continues. Alternatively, the Employer will be entitled to claim full damages.

 

		17	Transfer
                                         of an undertaking

 

	 	 	The Employee shall remain under the obligation to
    adhere the set out in the articles 10 through 16 of this Agreement vis-à-vis the Employer, if the enterprise of the
    Employer or a part thereof is transferred to a third party within the meaning of section 7:662 and onwards Dutch Civil Code
    and this Agreement terminates before or at the time of such transfer, whereas in the event of continuation of the Agreement
    the Employee would have entered the employment of the acquirer by operation of law.

 

		18	Other
                                         arrangements

 

	 	 	Subject to the provisions in this Agreement, the arrangements
    related to employment conditions adopted by the Employer from time to time, as laid down in the Employee Handbook are applicable.
    A copy of these arrangements has been provided to the Employee. By signing this agreement, the Employee acknowledges to have
    received and understood the Employee Handbook and the Insider Trading Policy.

 

		19	Employment
                                         costs regulation

 

	 	 	The conditions of employment costs regulation determined
    by the Employer apply. In this context, the Employer reserves the right at its sole discretion to modify certain fringe benefits,
    without any compensation in return.

 

		20	Amendment
                                         clause

 

		20.1	The
                                         Employer reserves the right to unilaterally amend the Agreement and the arrangements
                                         referred to in article 18 of this Agreement if it has such a serious interest in that
                                         respect entailing that the interests of the Employee must yield to that in accordance
                                         with standards of reasonableness and fairness.

 

		20.2	The
                                         Employer reserves the right to unilaterally amend the Agreement and the arrangements
                                         referred to in article 18 of this Agreement in the event of a relevant amendment of the
                                         law.

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 8
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

		21	Applicable
                                         law, no collective labour agreement

 

		21.1	This
                                         Agreement is governed by Dutch law.

 

		21.2	The
                                         Agreement is not subject to any collective labour agreement.

 

THIS AGREEMENT has been entered into on
the date stated at the beginning of this Agreement

 

	uniQure biopharma B.V.	 	Employee
	 	 	 	 
	/s/ Lilly Burggraaf	 	/s/ Sander van Deventer
	By:	Lilly Burggraaf	 	By: Sander van Deventer
	Title:	VP, Global Human Resources	 	 

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 9
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

Exhibit A

 

Job description Executive Vice President,
Research & Product Development

 

Reporting to the Chief Executive Officer,
the Executive Vice President, Research & Product Development will be responsible for the Employer’s research, scientific,
product development and technology platform strategy and activities in support of uniQure’s corporate strategy, including
basic and applied research projects, as well as the research and development of new processes, technologies and products.

 

Additionally, the Executive Vice President,
Research & Product Development will also provide guidance on scientific-related matters within the Company and represent uniQure
at scientific/medical conferences, as well as with investors and regulatory agencies. Duties will be performed on behalf of Employer
and, as needed, Employer’s subsidiaries and affiliates.

 

Job Responsibilities:

 

		·	Develop and implement strategies related
to research, product development (including analytical development, process development and vector development) and technology
development (including new AAV vectors, promoters, etc.) that support and enhance the corporate long-term plan;
	 	 	 
		·	Effectively communicate a vision and plan
related to new product research and development, as well as scientific and technological matters;
	 	 	 
		·	In collaboration with the Chief Executive
Officer, Chief Medical Officer, Commercial leader and Business Development leader, define and support a process and criteria for
identifying new targets, indications and potential gene therapy product candidates;
	 	 	 
		·	Provide scientific guidance on strategic
and operating decisions, setting strategy and performance goals;
	 	 	 
		·	Regularly reporting to the Board and other
members of the organization to ensure transparency regarding the progress of research and platform development programs;
	 	 	 
		·	Work closely with the Executive Vice President,
Operations, Chief Medical Officer and other key leaders to ensure execution on a global R&D and technology strategy;
	 	 	 
		·	Provide strong scientific leadership for
the uniQure research, nonclinical, product development and enabling technology development teams;

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 10
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.com	 

 

     

    

 

		·	Work closely and collaboratively with Program
Management in the execution of R&D stage-gates;
	 	 	 
		·	Lead the effort to translate discovery research
into clinical-ready product candidates;
	 	 	 
		·	Establish and/or help to maintain relationships
with KOL’s and academic institutions, and serve as a key liaison between the Company and its external scientific advisors
and the investment community;
	 	 	 
		·	Identify and support the Business Development
leader in evaluating collaboration opportunities to gain access to key capabilities and provide leadership in managing such collaborations;
	 	 	 
		·	Provide scientific expertise in support of
product and clinical development activities;
	 	 	 
		·	Actively participate in the evaluation and
implementation of business development opportunities, including collaborations, in-licensing and acquisitions of product candidates
and technologies, including due diligence as required;
	 	 	 
		·	Actively participate in leadership team meetings,
Board meetings and other key operating mechanisms required of senior management and by the Chief Executive Officer;
	 	 	 
		·	Make and attend scientific and investor presentations,
and participate in key scientific, medical and investor conferences; 
	 	 	 
		·	Support the establishment of and collaboration
with a Scientific Committee of the Board that will work with management and the Board of Directors to provide feedback and oversite
regarding R&D and technology strategy; 
	 	 	 
		·	Develop budgets for relevant functional responsibilities,
subject to approval by the Chief Executive Officer and Chief Accounting Officer, and ensure execution within approved targets;

	 	 	 
		·	Foster and develop an innovative and productive
organization of talented employees, including the management, motivation, recruitment and evaluation of personnel;
	 	 	 
		·	Responsible for definition, implementation,
maintenance and continued improvement of processes and systems, supported by meaningful Key Performance Indicators (KPI’s);
	 	 	 
		·	Constructively and collaboratively interacts
with staff of other disciplines, such as Finance, Operations, Human Resources, Commercial, Legal, Business Development, Investor
Relations and Clinical Development to ensure efficient day-to-day cooperation and success for the business; and

 

  Any other duties as may from time to time be assigned by the Employer and which are commensurate with Executive Vice President, Research & Product Development’s senior executive status.

 

    
	Paasheuvelweg 25a	Chamber of Commerce:	 11
	P.O. Box 22506	34275365	 
	1100 DA Amsterdam, NL	legal entity: uniQure biopharma B.V.	 
	 	 	 
	T: +31 20 240 6000	www.uniQure.com	 
	F: +31 20 240 6020	info@uniQure.comExhibit 10.3

 

September 16, 2019

 

Scott T. McMillan

109 Hayward Road

Acton, MA 01720

 

Re:        Separation from Employment

 

Dear Scott,

 

As we have discussed, the purpose of this
letter agreement (“Agreement”) is to set forth our mutual understanding and agreement concerning the terms and conditions
of your separation from employment with uniQure, Inc. (the “Company”), which generally are described in the Employment
Agreement between you and the Company dated July 10, 2017 (the “Employment Agreement”). In consideration of the mutual
promises set forth below, we have agreed as follows:

 

	1.	Separation from Employment. You will resign, and your separation from employment shall be
effective on August 31, 2019 (your “Separation Date”). You shall have relinquished as of that date any and all
positions that you have held with the Company. You shall not be considered an employee of the Company for any purpose after that
date. Effective as of August 19, 2019 through and including the Separation Date (the “Garden Leave Period”), you will
be on garden leave until the Separation Date without access to the Company’s facilities or electronic systems and your responsibility
and duties during that time will be to provide reasonable consultation and assistance on an as needed basis to the Chief Executive
Officer and the Executive Vice President, Operations (the “Company Officers”) with any transition matters or issues.
All business transacted on behalf of the Company during the Garden Leave Period shall be only with the Company Officers.

 

	2.	Final Compensation. Regardless of whether you accept this Agreement, on your Separation
Date, the Company shall provide you with your Accrued Benefits, as that term is defined in the Employment Agreement. Specifically,
the Company shall provide you with final payment of base salary due for time worked through the Separation Date as well as payment
for any accrued but unused vacation time. You agree that such payment represents all compensation to which you are entitled in
connection with your employment. Any additional requests by you for reimbursement of business expenses must be submitted for payment
using the Company’s standard expense reimbursement system no later than the Separation Date.

 

	3.	Separation Payment. Subject to: (i) the Company’s receipt of this Agreement signed
by you; (ii) your full acceptance of the terms of, and full performance under, this Agreement (including, without limitation, your
acceptance of the general release of legal claims contained in Paragraph 9 below (the "General Release")); (iii) your
satisfactory performance of the responsibilities and duties of your position with the Company up through your Separation Date,
and (iv) the expiration of the seven (7) day revocation period contained in Paragraph 11 below (the "Revocation Period")
without revocation):

 

     

    
Scott T. McMillan
Separation Agreement
Page 2

    

 

a.      
the Company agrees to provide you with a lump sum severance payment equal to 100% of your annual base salary of Three Hunderd Ninety-One
Thousdand Six Hundred Forty-Four Dollars ($391,644) less all applicable federal, state and local taxes and other withholdings (the
"Separation Payment"). The Separation Payment will be made to you no later than thirty (30) days following the date you
sign and deliver this Agreement to the Company and after the Revocation Period has expired without any notice of revocation by
you. You will also receive an accelerated vesting of the Performance Share Units grant to you dated January 26, 2018 as provided
in Section 6 below.

 

b.     
Provided that you and your eligible dependents, if any, are participating in the Company’s group health, dental and vision
plans on the termination date and elect on a timely basis to continue that participation in some or all of the offered plans through
the federal law commonly known as “COBRA,” the Company will pay or reimburse you for your full COBRA premiums (i.e.,
employer and employee portion) until the earlier to occur of: (a) eighteen (18) months from the Separation Date, (b) the date you
become eligible to enroll in the health, dental and/or vision plans of another employer, (c) the date you (and/or your eligible
dependents, as applicable) are no longer eligible for COBRA coverage, or (d) the Company in good faith determines that payments
under this paragraph would result in a discriminatory health plan pursuant to the Patient Protection and Affordable Care Act of
2010, as amended, and any guidance or regulations promulgated thereunder (collectively, “PPACA”). You agree to notify
the Company promptly if you become eligible to enroll in the plans of another employer or if you or any of your dependents cease
to be eligible to continue participation in the Company’s plans through COBRA.

 

	4.	Tax Provision. In connection with the Separation Payment provided to you pursuant to this
Agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall
be responsible for all applicable taxes with respect to such Separation Payment under applicable law. The Company does not guarantee
any particular tax effect for any of the payments or other consideration set forth in this Agreement, and you shall be solely responsible
and liable for the satisfaction of all taxes, penalties and interest that may be imposed on you or for your account in connection
with the Agreement (including any taxes, penalties and interest under IRC Section 409A), and the Company shall not have any obligation
to indemnify or otherwise hold you (or any beneficiary) harmless from any or all of such taxes, penalties or interest. You acknowledge
that you are not relying upon advice or representation of the Company with respect to the tax treatment of any of the separation
benefits set forth in this Agreement.

 

	5.	Health Insurance Continuation. Regardless of whether you accept this Agreement, you will
remain on the Company’s insured health plan at the level(s) you are currently enrolled, through August 31, 2019. Notice of
your rights and obligations concerning continuation of coverage shall be sent to you under separate cover in accordance with applicable
law.

 

     

    
Scott T. McMillan
Separation Agreement
Page 3

    

 

	6.	Status of Employee Benefits and Stock Options. Except as otherwise expressly provided in
Section 5 of this Agreement, your participation in all employee benefit plans of the Company shall end as of your Separation Date
in accordance with the terms of those plans. Information will be provided on terminating participation in all plans, including
either maintaining your existing 401k account, or rolling it over to another provider. The Company confirms that you will have
vested Stock Options, Performance Share Units (“PSUs”), and Restricted Share Units (“RSU’s”) as of
your Separation Date pursuant to the terms of your grants. Stock Options may be exercised pursuant to the terms and conditions
of your Share Option Agreements and the Company’s Amended and Restated 2014 Share Incentive Plan. Your Performance Share
Units granted in January 2018 (totaling 7045 shares) will have a Vesting Date (as defined in the grant agreement) of September
19, 2019. You will not be eligible to participate in the Company Employee Stock Purchase Plan (“ESPP”) for the offering
period beginning September 1, 2019. For the offering period from June 1, 2019 through August 31, 2019, the Company will refund
any payroll contributions that you made pursuant to the ESPP, and no stock will be purchased on your behalf. This Agreement does
not grant or promise to grant any equity, and, except where expressly provided, does not modify the terms of any prior grant of
equity or modify the terms of any agreement signed pursuant to a grant of equity. The terms of the grants of equity and agreements
signed pursuant to grants of equity shall control in case of conflict with this Agreement.

 

	7.	Confidentiality. As a material inducement to the Company to enter into this Agreement, you
agree to keep the fact of this Agreement (including any negotiations or discussions related hereto), the amount of the payments,
other consideration, and the terms of this Agreement (“Agreement-Related Information”), in complete confidence. Except
as you may be required by local, state or federal law or regulation or by compulsory process of law, and provided that in case
of such requirement you shall immediately, unless precluded by law, notify the Company of such requirement in writing, you agree
that neither you nor any person acting by, through, under, or in concert with you will, at any time, disclose Agreement-Related
Information, except for disclosures: (i) to an attorney of your choice who may be advising you in connection with this Agreement;
(ii) to your accountant or tax preparer; or (iii) to your immediate family, provided that all such persons to whom you disclose
such information are first advised by you prior to such disclosure of the confidential nature of the information and your obligations
under this Agreement, and further provided that the subsequent disclosure by any such persons of the amount of this settlement
or the terms of this Agreement will be treated as if you had made such disclosure; and (iv) and, in any event, you shall at no
time disclose Agreement-Related Information to any current or former employee of the Company.

 

     

    
Scott T. McMillan
Separation Agreement
Page 4

    

 

	8.	Non-Disparagement/Cooperation. You agree, to the extent permitted by law, that you will
not, at any time after the date hereof, make any remarks or comments, orally or in writing, to any customer, potential customer,
partner, supplier, employee, shareholder, potential investor, or any other person, which or who have, or could reasonably be anticipated
to have, business dealings with the Company, which remarks or comments reasonably could be construed to be derogatory or disparaging
to the Company or any of its shareholders, officers, directors, employees, attorneys or agents, or which reasonably could be anticipated
to be damaging or injurious to the Company’s reputation or good will or to the reputation or good will of any person associated
with the Company. Notwithstanding the above, your non-disparagement obligation shall not prohibit you from testifying truthfully
in any legal proceeding.

 

	9.	General Release.

 

(a)   
 You hereby irrevocably
and unconditionally release, acquit and forever discharge the Company, its parent entities and corporations, subsidiaries (whether
wholly or partially owned), divisions, affiliates, predecessors, successors and assigns, and its and their respective current and
former partners, owners, agents, directors, officers, fiduciaries, employees, supervisors, managers, representatives, attorneys,
insurers and reinsurers, and all persons and entities acting by, through, under or in concert with the Company or any of the aforementioned
entities or individuals, in their personal and professional capacities (collectively the "Releasees"), from any and all
claims, demands, and causes of action of whatever kind or nature, including without limitation, all claims, demands, and causes
of action arising from your employment or separation from employment with the Company, that you or your heirs, executors, administrators,
successors or assigns have, may have, or have at any time had, prior to the date you sign this Agreement against the Releasees,
or any of them, whether arising under tort, contract, or other law and whether arising under state, federal, or other law including,
but not limited to, Title VII of the Civil Rights Act of 1964 and as amended by the Civil Rights Act of 1991, 42 U.S.C. §§
2000e, et seq.; the Americans with Disabilities Act, 42 U.S.C. §§ 12101, et seq, as amended; the Age Discrimination
in Employment Act (including, without limitation, the Older Workers' Benefit Protection Act), 29 U.S.C. §§ 623, et
seq.; the National Labor Relations Act, as amended, 29 U.S.C., § 151 et seq.; the Occupational Safety and Health
Act, as amended; the Immigration Reform Control Act, as amended; § 503 of the Rehabilitation Act of 1973, 29 U.S.C. §§
701, et seq.; the Civil Rights Act of 1866, 42 U.S.C. § 1981; except as otherwise provided herein the Consolidated
Omnibus Budget Reconciliation Act of 1985, 42 U.S.C. § 1395(c); Executive Order 11246; the Employee Retirement Income Security
Act, 29 U.S.C. §§ 1132 (a)(l)(B), et seq.; the federal Workers Adjustment and Retraining Notification Act, 29
U.S.C. §§ 2101 et seq.; Sarbanes- Oxley Act of 2002, Public Law 107-204, including whistleblowing claims under 18 U.S.C.
§§ 1514A and 1513(e); the Family and Medical Leave Act, 29 U.S.C. §§ 2601 et seq; all claims arising
out of the claims under the MA Fair Employment Practices Act, M.G.L. c. 151B, the MA Wage and Hour laws, M.G.L. c. 149, et. al.,
M.G.L. c. 93, and all other claims and rights under any other federal, state, and local statutory and common law, including but
not limited to public policy, contract and tort and any and all claims arising from any injuries or damages suffered by you, for
attorney's fees, costs, non- payment, or any other claim or damage you could assert against the Company and/or the Releasees. For
the avoidance of doubt, this release includes any claims under the under the Massachusetts Wage Act and State Overtime Laws, including
without limitation G.L. c. 149 § 148, 150 et seq. and G.L. c. 151 § lA et seq. You promise not to sue any
of the Releasees on any of these released claims.

 

     

    
Scott T. McMillan
Separation Agreement
Page 5

    

 

(b)   
You represent and warrant to the Company that no portion of any claim, demand, cause of action, or other matter released by you
herein, nor any portion of any recovery or settlement to which you might be entitled from any Releasee, has been assigned or transferred
to any other person or entity, either directly or by way of subrogation or operation of law.

 

(c)   
You acknowledge that you have been granted by the Company all requested paid and/or unpaid leave to which you may have been entitled.
You represent that you are not aware of any facts that would support a claim by you against any of the Releasees for any violation
of the Family and Medical Leave Act. You further acknowledge that you have been properly paid for all time worked and are unaware
of any facts that would support a claim by you against any of the Releasees for any claim of unpaid wages or overtime or any other
violation of the Fair Labor Standards Act or state wage and hour law.

 

Notwithstanding
the above, this Release does not include and shall not preclude (a) any rights to any vested benefits or vested rights under
employee benefit plans under the Employee Retirement Income Security Act (29 U.S.C. § 1001 et seq.), as amended; (b) any claims
arising from a breach of this Agreement or rights to enforce this Agreement; (c) any action or proceeding against the Company for
acts, incidents, occurrences, or inactions occurring after the execution of this Agreement and (d) any rights to indemnification
that exist as of the Separation Date by the Company and/or the Company’s insurers from any claims against you by any third
party involving your employment with the Company.

 

	10.	Protected Rights. You understand that nothing contained in this Agreement limits your ability
to file a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational
Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency
or commission (“Government Agencies”). You further understand that this Agreement does not limit your ability to communicate
with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government
Agency, including providing documents or other information, without notice to the Company. You understand that you waive and release
any personal entitlement to reinstatement, back pay, or any other types of damages, or injunctive relief, in connection with any
actions taken by you on your behalf on your complaint or charge. You understand that by executing the General Release, you are
forever releasing and waiving any and all claims against the Releasees.

 

     

    
Scott T. McMillan
Separation Agreement
Page 6

    

 

	11.	Acknowledgments. You acknowledge and agree that you understand the meaning of this Agreement
and that you freely and voluntarily enter into it and the General Release. You agree that no fact, evidence, event, or transaction,
whether known or unknown, shall affect in any manner the final and unconditional nature of this Agreements and the General Release.
Pursuant to the Older Workers Benefit Protection Act, you acknowledge that you have been advised:

 

(i)  
that you have twenty-one (21) days to consider this Agreement and General Release;

 

(ii) 
any modifications to this Agreement, whether material or immaterial, will not restart the twenty-one (21) day consideration period;

 

(iii)  
to consult with an attorney prior to executing this Agreement and General Release;

 

(iv)  
by signing this Agreement and General Release you will give up important legal rights, including the right to sue the Company;

 

 (v)  this Agreement and General Release does not release any claims that arise after the execution of this Agreement and General Release; and

 

(vi)  
for a period of seven (7) days after executing this Agreement and General Release, you may revoke this Agreement and General Release
by providing written notice of said revocation to me at the address of the Company set forth above, and this Agreement and General
Release shall not become effective or enforceable until said seven-day period has expired without your revocation.

 

In the event that you execute this Agreement
and General Release prior to the expiration of the twenty-one (21) day period during which you may consider it, you represent and
acknowledge that you have done so voluntarily and of your own free will without any coercion or compulsion of any nature by the
Company or anyone associated with the Company.

 

	12.	Acknowledgement of Confidentiality, Developments and Restrictive Covenants Agreement. You
acknowledge that you are bound by the Company’s Confidentiality, Developments, and Restrictive Covenants Agreement, which
copy is attached here as Exhibit 1 (the “Confidentiality Agreement”), including, without limitation, the provisions
regarding confidentiality, disclosure and assignment of inventions, non-competition, non-solicitation, disclosure of certain provisions
to future employers, tolling of post-employment obligations, and return of Company property. You further acknowledge that, pursuant
to Section 8 of the Confidentiality Agreement, the Confidentiality Agreement shall survive your separation from the Company. (In
case of a conflict between this Agreement and the Confidentiality Agreement, this Agreement shall control). You also acknowledge
and represent that you have returned all property of the Company as required in Section 19 of the Confidentiality Agreement, including,
without limitation, all documents, devices, equipment, keys, security passes, credit cards, hardware, data, databases, source code,
object code, and data or computer programming code stored on an optical or electronic medium, and any copies thereof, relating
to uniQure’s business and affairs, including any Confidential Information or any reference thereto, and you further represent
that you are in compliance with Section 19 of the Confidentiality Agreement. Notwithstanding the foregoing, nothing in Exhibit
1 or set forth herein is intended to or shall interfere with your rights under the Defend Trade Secrets Act of 2016 which provides,
in part, that “[a]n individual shall not be held criminally or civilly liable under any federal or state trade secret law
for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either
directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation
of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

 

     

    
Scott T. McMillan
Separation Agreement
Page 7

    

 

	13.	Consulting. You agree that you will provide consulting services to the Company as requested
on an as-needed basis for the period from September 1, 2019 through and including October 31, 2019 (the “Consulting Period”).
You will provide consulting services consistent with your current position with the Company and assist in the transition of the
manufacturing and operations organization. Such services will be directed by the Executive Vice President, Operations, and may
include consulting services related to manufacturing, operations, product development, project management, human resources issues,
and other related fields. The services shall be limited to no more than eight hours per week. As compensation, you will receive
payments totaling thirteen thousand ninety-one dollars ($13,091.00) (the “Consulting Fee”). The Consulting Fee will
be paid in two installments: one-half with the Separation Payment and one-half within thirty days of the end of the Consulting
Period. For clarity, the parties intend that your grants of equity in the Company will continue to vest during the Consulting Period
on the same terms as if you had remained an employee of the Company during that period, and will cease to vest immediately following
the end of the Consulting Period.

 

	14.	Governing Law and Interpretation. This Agreement shall be construed in accordance with the
laws of the Commonwealth of Massachusetts without regard to choice or conflict of law principles. The language of all parts of
this Agreement shall be construed as a whole, according to its fair meaning, and not strictly for or against either party.

 

	15.	Interpretation of Agreement. This Agreement sets forth the entire agreement between the
parties pertaining to the subject matter hereof. Notwithstanding the foregoing, this Agreement does not abrogate, limit, or otherwise
impair any of the Company’s rights or any of your post-employment obligations under the Confidentiality, Developments and
Restrictive Covenants Agreement. Likewise, this Agreement does not supersede or impair any of the terms or condition of any Performance
Share Unit Agreement, Share Option Agreement, or the Company’s Amended and Restated 2014 Share Incentive Plan.

 

     

    
Scott T. McMillan
Separation Agreement
Page 8

    

 

	16.	No Reliance. You represent and acknowledge that, in executing this Agreement, you do not
rely and have not relied upon any representation or statement outside this written agreement made by any of the Releasees or by
any of the Releasees’ agents, representatives or attorneys with regard to the subject matter, basis or effect of this
Agreement.

 

	17.	Waiver. Failure to insist on compliance with any term, covenant or condition contained in
this Agreement shall not be deemed a waiver of that term, covenant or condition, nor shall any waiver or relinquishment
of any right or power contained in this Agreement at any one time or more times be deemed a waiver or relinquishment of any right
or power at any other time or times.

 

	18.	Severability and Modification. Should any term or provision of this Agreement be declared
illegal, invalid or unenforceable by any court of competent jurisdiction and if such provision cannot be modified to be enforceable,
such provision shall immediately become null and void, leaving the remainder of this Agreement in full force and effect. Provided
however, if your General Release is found invalid, illegal, and/or unenforceable, you agree to
enter into a full and General Release with the Company that is not invalid, illegal and/or unenforceable without payment of additional
consideration. 

 

	19.	Amendment. This Agreement shall be binding upon the parties and may not be modified in any
manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties
hereto. This Agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs,
executors, successors and administrators.

 

	20.	Representation. You represent that the Company has advised you, and you have had the opportunity,
to thoroughly discuss all aspects of this Agreement with legal counsel, that you have read and understand the provisions
herein, and that you are voluntarily entering into this Agreement.

 

	 	uniQure, Inc.
	 
	 	/s/ Matthew Kapusta
	 	By:	Matthew Kapusta
	 	 	Chief Executive Officer

 

     

    
Scott T. McMillan
Separation Agreement
Page 9

    

 

	AGREED TO AND EXECUTED THIS 16th DAY OF SEPTEMBER
    2019.
	 
	/s/ Scott T. McMillan	 
	Scott T. McMillan	 

 

     

    
Scott T. McMillan
Separation Agreement
Page 10

    

 

EXHIBIT 1

 

Confidentiality,
Developments, and Restrictive Covenants Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]